Celldex Therapeutics closed a public offering of 11.9 million shares, raising approximately $345 million at $29 per share.
Quiver AI Summary
Celldex Therapeutics, Inc. has completed its underwritten public offering of 11,896,750 shares of common stock, raising approximately $345 million in gross proceeds. This includes the full exercise of an underwriter option for an additional 1,551,750 shares at a price of $29.00 per share, with all shares being sold by Celldex. The offering was managed by Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor, with LifeSci Capital and H.C. Wainwright & Co. as co-lead managers. The shares were offered under a previously effective registration statement with the SEC. The final terms are provided in a prospectus supplement available on the SEC website and through contacting the underwriting firms. Celldex specializes in developing therapeutics targeting mast cell biology for severe diseases, positioning itself as a leader in innovative biotechnology solutions.
Potential Positives
- The successful closing of a public offering of approximately $345 million provides Celldex with significant funding to advance its clinical programs and research initiatives.
- The offering included the full exercise of the underwriters' option for additional shares, indicating strong demand for Celldex's stock in the market.
- This capital raise enhances Celldex's financial position, enabling the company to potentially accelerate the development of its pipeline of therapeutics.
Potential Negatives
- The company is relying on the issuance of additional shares to raise funds, which may dilute existing shareholder value.
- The need for a public offering suggests potential liquidity issues or a lack of sufficient operational cash flow.
- The press release does not address how the raised funds will be specifically utilized, leaving investors uncertain about the company's financial strategy.
FAQ
What is the amount raised in Celldex's recent public offering?
Celldex raised approximately $345 million through its recent public offering of common stock.
How many shares of common stock were offered by Celldex?
Celldex offered a total of 11,896,750 shares of its common stock in the public offering.
Who managed the Celldex public offering?
Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor acted as joint bookrunning managers for the offering.
Where can I find the final prospectus for Celldex's offering?
The final prospectus is available on the SEC's website and can be obtained by contacting Leerink Partners or TD Securities.
What area of medicine does Celldex focus on?
Celldex focuses on developing innovative therapeutics for severe inflammatory, allergic, autoimmune, and other serious diseases.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CLDX Insider Trading Activity
$CLDX insiders have traded $CLDX stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $CLDX stock by insiders over the last 6 months:
- RICHARD M. WRIGHT sold 49,298 shares for an estimated $1,183,176
- FREDDY A. JIMENEZ (SVP & GENERAL COUNSEL) sold 4,166 shares for an estimated $121,209
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CLDX Hedge Fund Activity
We have seen 77 institutional investors add shares of $CLDX stock to their portfolio, and 80 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP added 2,279,605 shares (+39.3%) to their portfolio in Q4 2025, for an estimated $61,914,071
- POINT72 ASSET MANAGEMENT, L.P. removed 2,135,585 shares (-54.8%) from their portfolio in Q4 2025, for an estimated $58,002,488
- BRAIDWELL LP added 1,266,420 shares (+214.0%) to their portfolio in Q4 2025, for an estimated $34,395,967
- STATE STREET CORP added 555,579 shares (+19.5%) to their portfolio in Q4 2025, for an estimated $15,089,525
- ADAR1 CAPITAL MANAGEMENT, LLC added 537,325 shares (+491.0%) to their portfolio in Q4 2025, for an estimated $14,593,747
- COMMODORE CAPITAL LP removed 463,335 shares (-15.3%) from their portfolio in Q4 2025, for an estimated $12,584,178
- DIMENSIONAL FUND ADVISORS LP added 394,633 shares (+153.5%) to their portfolio in Q4 2025, for an estimated $10,718,232
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CLDX Analyst Ratings
Wall Street analysts have issued reports on $CLDX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Mizuho issued a "Outperform" rating on 10/21/2025
- Barclays issued a "Underweight" rating on 10/13/2025
To track analyst ratings and price targets for $CLDX, check out Quiver Quantitative's $CLDX forecast page.
$CLDX Price Targets
Multiple analysts have issued price targets for $CLDX recently. We have seen 4 analysts offer price targets for $CLDX in the last 6 months, with a median target of $41.0.
Here are some recent targets:
- Richard Law from Goldman Sachs set a target price of $34.0 on 03/02/2026
- Alex Thompson from Stifel set a target price of $68.0 on 02/26/2026
- Etzer Darout from Barclays set a target price of $24.0 on 12/17/2025
- Joseph Catanzaro from Mizuho set a target price of $48.0 on 10/21/2025
Full Release
HAMPTON, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten public offering of 11,896,750 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase an additional 1,551,750 shares of common stock at a public offering price of $29.00 per share. All of the shares sold in the offering were sold by Celldex. The gross proceeds to Celldex from this offering were approximately $345 million, excluding underwriting discounts and commissions and other offering-related expenses.
Leerink Partners, TD Cowen, Guggenheim Securities and Cantor acted as joint bookrunning managers for the offering. LifeSci Capital and H.C. Wainwright & Co. acted as co-lead managers for the offering.
The securities described above were offered and sold by Celldex pursuant to a shelf registration statement on Form S-3 (File No. 333-275300), which was previously filed with the Securities and Exchange Commission (“SEC”) and became automatically effective on November 3, 2023. This offering was made only by means of a prospectus supplement and the accompanying prospectus that form a part of the registration statement. The final terms of the offering are disclosed in a final prospectus supplement which has been filed with the SEC and is available on the SEC’s website located at http://www.sec.gov . Copies of the final prospectus supplement and the accompanying base prospectus may be obtained for free by contacting Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105 or by email at [email protected] or TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at [email protected] .
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Celldex
Celldex is a clinical stage biotechnology company leading the science at the intersection of mast cell biology and the development of transformative therapeutics for patients. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases.
Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration Celldex Therapeutics, Inc.
(508) 864-8337
[email protected]
Patrick Till Meru Advisors
(484) 788-8560
[email protected]
Source: Celldex Therapeutics, Inc.
